智通财经APP获悉，摩根士丹利发布研报称，微创医疗(00853)面临持续的国内监管挑战，但在手术机械人(Medbot)、心血管和血管介入业务的出口动能强劲，预期2026年有望实现收支平衡;又因心律管理(CRM)义务已解决，主要股东Otsuka已完成撤出，因此将该股目标价由原先8.6港元上调至16港元，相当于预测2027年市盈率约20倍。维持“与大市同步”评级。
大摩将微创医疗2025至2027年销售预测下调约2%，反映2024至2027年11%的年均复合增长率;预期2026年净利润实现收支平衡(不变)，2026至2027年净利润预测从低基数分别上调151%、15%。大摩又将其控股公司折让从40%收窄至30%，以反映流动性担忧减少;毛利率预测亦根据指引上调。随着持续的成本节约措施，大摩相应削减对其营运支出预测。大摩现预测公司2025年营运层面从微薄基数实现收支平衡，料2025年净亏损收窄93%至约5,500万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.